42 related articles for article (PubMed ID: 38615378)
1. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study.
Eigendorff F; Filimonova I; Scholl S; Sayer-Klink A; Rummler S; Kunert C; Pietschmann K; Wittig A; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2024 May; 150(5):224. PubMed ID: 38693452
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL.
Wang X; Deng Y; He G; Lai S; Li Y; Zhang S; He Y; Han Y; Zhang L; Su Y; Liu F; Yi H
Hematology; 2024 Dec; 29(1):2356300. PubMed ID: 38776229
[TBL] [Abstract][Full Text] [Related]
3. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
[TBL] [Abstract][Full Text] [Related]
4. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients.
Tomasik J; Bilicki D; Basak GW
Expert Opin Biol Ther; 2024 May; 24(5):389-397. PubMed ID: 38725262
[TBL] [Abstract][Full Text] [Related]
6. [Impact of autologous hematopoietic stem cell transplantation on the efficacy of CAR-T treatment of relapsed/refractory multiple myeloma].
Ding MJ; Jie XX; Li HJ; Xu ZY; Nian L; Qi KM; Yan ZL; Zhu F; Cao J; Zhang HX; Xu KL; Cheng H; Li ZY
Zhonghua Nei Ke Za Zhi; 2024 Jun; 63(6):587-592. PubMed ID: 38825927
[No Abstract] [Full Text] [Related]
7. Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China.
Wang W; Zhang W; Su LP; Liu LH; Gao YH; Wang QS; Su H; Song YQ; Zhang HL; Shen J; Jing HM; Wang SY; Cen XN; Liu H; Liu AC; Li ZJ; Luo JM; He JX; Wang JW; O'Connor OA; Zhou DB
Ann Hematol; 2024 May; ():. PubMed ID: 38805037
[TBL] [Abstract][Full Text] [Related]
8. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.
Choquet S; Soussain C; Azar N; Morel V; Metz C; Ursu R; Waultier-Rascalou A; di Blasi R; Houot R; Souchet L; Roos-Weil D; Uzunov M; Quoc SN; Jacque N; Boussen I; Gauthier N; Ouzegdouh M; Blonski M; Campidelli A; Ahle G; Guffroy B; Willems L; Corvilain E; Barrie M; Alcantara M; le Garff-Tavernier M; Psimaras D; Weiss N; Baron M; Bravetti C; Hoang-Xuan K; Davi F; Shor N; Alentorn A; Houillier C
Am J Hematol; 2024 Jul; 99(7):1240-1249. PubMed ID: 38586986
[TBL] [Abstract][Full Text] [Related]
9. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Clin Exp Med; 2024 May; 24(1):105. PubMed ID: 38771501
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers.
Ahmed N; Sun F; Teigland C; Kilgore KM; Mohammadi I; Chambers J; Dieyi C; Feng C; Osborn J; Fu C; Gergis U
Transplant Cell Ther; 2024 Apr; ():. PubMed ID: 38697294
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study.
Tun AM; Patel RD; St-Pierre F; Ouchveridze E; Niu A; Thordardottir T; Obasi J; Rosenthal A; Pophali PA; Fenske TS; Karmali R; Ahmed S; Johnston PB
Am J Hematol; 2024 Jun; ():. PubMed ID: 38837403
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.
Iacoboni G; Iraola-Truchuelo J; O'Reilly M; Navarro V; Menne T; Kwon M; Martín-López AÁ; Chaganti S; Delgado J; Roddie C; Pérez A; Norman J; Guerreiro M; Gibb A; Caballero AC; Besley C; Martínez-Cibrián N; Mussetti A; Sanderson R; Luzardo H; Iyengar S; Sánchez JM; Jones C; Sancho JM; Barba P; Latif AL; López-Corral L; Hernani R; Reguera JL; Sureda A; Garcia-Sancho AM; Bastos M; Abrisqueta P; Kuhnl A
Hemasphere; 2024 May; 8(5):e62. PubMed ID: 38774657
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation.
Zhou F; Du F; Wang Z; Xue M; Wu D; Chen S; He X
J Hematol Oncol; 2024 May; 17(1):34. PubMed ID: 38764055
[TBL] [Abstract][Full Text] [Related]
14. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
Ghilardi G; Williamson S; Pajarillo R; Paruzzo L; Chen L; Grady C; Doucette A; Nemecek E; Gabrielli G; Barta SK; Svoboda J; Chong EA; Yelton R; Nasta SD; Landsburg DJ; Ugwuanyi O; Chen AI; Schachter L; White G; Ballard HJ; Weber E; Curley C; Porter DL; Garfall AL; Hwang WT; Guerra CE; Maziarz RT; Schuster SJ; Ruella M
NEJM Evid; 2024 Apr; 3(4):EVIDoa2300213. PubMed ID: 38776868
[TBL] [Abstract][Full Text] [Related]
15. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
[TBL] [Abstract][Full Text] [Related]
16. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
17. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.
Liu W; Liu W; Zou H; Chen L; Huang W; Lv R; Xu Y; Liu H; Shi Y; Wang K; Wang Y; Xiong W; Deng S; Yi S; Sui W; Peng G; Ma Y; Wang H; Lv L; Wang J; Wei J; Qiu L; Zheng W; Zou D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631712
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.
Xin X; Zhu X; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Li C; Cao Y; Meng F; Jiang L; Zhang Y
Cell Oncol (Dordr); 2024 Apr; ():. PubMed ID: 38564164
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
